Sutro Biopharma’s Q1 2026 update underscores active clinical development of STRO-004 in solid tumors with dosing underway in higher cohorts and initial data expected mid-year. The firm is leveraging its XpressCF® and XpressCF+® platforms to develop differentiated antibody drug conjugates (ADCs), including next-generation dual-payload and immunostimulatory formats. Recent corporate restructuring has refocused resources on three preclinical ADC assets, extending the cash runway into 2027. While technology-driven collaborations provide financial backing, clinical execution and competitive oncology dynamics remain key watchpoints.